Predictive Value of Monocyte to High-Density Lipoprotein Cholesterol Ratio (MHR) in Schizophrenia Patients with Stable Coronary Artery Disease
Yıl: 2022 Cilt: 32 Sayı: 1 Sayfa Aralığı: 77 - 83 Metin Dili: İngilizce DOI: 10.54005/geneltip.1032165 İndeks Tarihi: 29-07-2022
Predictive Value of Monocyte to High-Density Lipoprotein Cholesterol Ratio (MHR) in Schizophrenia Patients with Stable Coronary Artery Disease
Öz: Aim: We aimed to investigate whether the monocyte/high-density lipoprotein ratio (MHR) has
a potential value in the diagnosis of schizophrenia and in predicting the presence of comorbid
coronary artery disease (SPCAD).
Material and Method: A total of 281 participants were enrolled in this cross-sectional study. Of the
participants, 85 (Group 1) were diagnosed with schizophrenia and stable coronary artery disease,
and 92 (Group 2) were diagnosed with only schizophrenia. 104 (Group 3) participants in the control
group had no disease.
Results: MHR was highest in group 1 and higher in group 2 than in group 3. Group 1 was 18.91
(13.38-23.60) group 2: 13.68 (11.11-16.66) and group 3: 12.50 (9.13-15.68), respectively; p<0.001 for
both). Conversely, HDL was the lowest in group 1, while it was lower in group 2 than in group 3 (38.52
± 9.45 vs. 42.76 ± 9.12 vs. 47.00 ± 11.87, respectively p<0.05 for both). The cutoff value of MHR for
SPCAD was 12.77, with a sensitivity of 79% and a specificity of 43%. This value for SP was 10.73, with
a sensitivity of 79% and a specificity of 50%.
Conclusion: High MHR which indicates an enhanced inflammation and oxidative stress was found
a significant and independent marker in SP and SPCAD.
Anahtar Kelime: Stabil Koroner Arter Hastalığı Olan Şizofreni Hastalarında Monosit/Yüksek Yoğunluklu Lipoprotein (MHR) Oranının Öngördürücülüğü
Öz: Amaç: Bu çalışmada şizofreni ve stabil koroner arter hastalığı olan şizofreni hastalarında (SKAH-Ş)
monosit/yüksek yoğunluklu lipoprotein oranının (MHO) tanıda öngördürücü değerinin olup
olmadığını araştırmayı amaçladık.
Gereç ve yöntem: Bu kesitsel çalışmaya toplam 281 katılımcı alındı. Katılımcıların 85’ine şizofreni ve
stabil koroner arter hastalığı (Grup 1), 92’sine ise sadece şizofreni (Grup 2) tanısı konuldu. Kontrol
grubundaki 104 katılımcının (Grup 3) ise hiçbir hastalığı yoktu.
Bulgular: MHO grup 1’de en yüksek iken grup 2’de grup 3’e göre daha yüksekti (grup 1: 18.91
(13.38-23.60); grup 2: 13.68 (11.11-16.66); grup 3: 12.50 (9.13-15.68); her iki karşılaştırma için p <0.001).
Buna zıt olarak, HDL grup 1’de en düşük iken grup 2’de grup 3’e göre daha düşüktü (grup 1: 38.52
± 9.45; grup 2: 42.76 ± 9.12; grup 3: 47.00 ± 11.87; her iki karşılaştırma için p <0.05). MHO’ nun
kesme puanı stabil koroner arter hastalığı olan şizofreni hastalarında 12.77 ve üzeri alındığında
duyarlılık %79, özgüllük ise %43 bulundu. Sadece şizofreni hastalarında ise kesme değeri 10.73 ve
üzeri alındığında duyarlılık % 79, özgüllük ise % 50 bulundu.
Sonuç: Artmış inflamasyon ve oksidatif stresi gösteren yüksek MHO, şizofreni ve stabil koroner arter
hastalığı olan şizofreni hastalarında önemli ve bağımsız bir belirteç olarak bulundu.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1.McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia-An Overview. JAMA psychiatry. 2019:1-10.
- 2.Liu J, Li M, Luo XJ, Su B. Systems-level analysis of risk genes reveals the modular nature of schizophrenia. Schizophrenia research. 2018;201:261-9.
- 3.Trépanier MO, Hopperton KE, Mizrahi R, Mechawar N, Bazinet RP. Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review. Molecular psychiatry. 2016;21(8):1009-26.
- 4.Gallego JA, Blanco EA, Husain-Krautter S, Madeline Fagen E, MorenoMerino P, Del Ojo-Jiménez JA, et al. Cytokines in cerebrospinal fluid of patients with schizophrenia spectrum disorders: New data and an updated meta-analysis. Schizophrenia research. 2018;202:64-71.
- 5.Karageorgiou V, Milas GP, Michopoulos I. Neutrophil-to-lymphocyte ratio in schizophrenia: A systematic review and meta-analysis. Schizophrenia research. 2019;206:4-12.
- 6.Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biological psychiatry. 2013;74(6):400-9.
- 7.Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biological psychiatry. 2011;70(7):663-71.
- 8.Guest PC. Insulin Resistance in Schizophrenia. Advances in experimental medicine and biology. 2019;1134:1-16.
- 9.Leonard BE, Schwarz M, Myint AM. The metabolic syndrome in schizophrenia: is inflammation a contributing cause? Journal of psychopharmacology (Oxford, England). 2012;26(5 Suppl):33-41.
- 10.Karanikas E, Antoniadis D, Garyfallos GD. The role of cortisol in first episode of psychosis: a systematic review. Current psychiatry reports. 2014;16(11):503.
- 11.Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. The New England journal of medicine. 2005;352(16):1685-95.
- 12.Ancuta P, Wang J, Gabuzda D. CD16+ monocytes produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells. Journal of leukocyte biology. 2006;80(5):1156-64.
- 13.Hansson GK. Inflammatory mechanisms in atherosclerosis. Journal of thrombosis and haemostasis : JTH. 2009;7 Suppl 1:328-31.
- 14.Kuvin JT, Rämet ME, Patel AR, Pandian NG, Mendelsohn ME, Karas RH. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. American heart journal. 2002;144(1):165-72.
- 15.Kuvin JT, Patel AR, Sidhu M, Rand WM, Sliney KA, Pandian NG, et al. Relation between high-density lipoprotein cholesterol and peripheral vasomotor function. The American journal of cardiology. 2003;92(3):275-9.
- 16.Soria-Florido MT, Schröder H, Grau M, Fitó M, Lassale C. High density lipoprotein functionality and cardiovascular events and mortality: A systematic review and meta-analysis. Atherosclerosis. 2020;302:36-42.
- 17.Wang P, Wang Y, Ma W, Li H, Chen H. High-density lipoprotein cholesterol and intracoronary thrombosis burden. Coronary artery disease. 2013;24(1):1-5.
- 18.Karataş MB, Çanga Y, Özcan KS, İpek G, Güngör B, Onuk T, et al. Monocyte to high-density lipoprotein ratio as a new prognostic marker in patients with STEMI undergoing primary percutaneous coronary intervention. The American journal of emergency medicine. 2016;34(2):240-4.
- 19.Wu TT, Zheng YY, Chen Y, Yu ZX, Ma YT, Xie X. Monocyte to highdensity lipoprotein cholesterol ratio as long-term prognostic marker in patients with coronary artery disease undergoing percutaneous coronary intervention. Lipids in health and disease. 2019;18(1):180.
- 20.KIZILTUNÇ E, Alsancak Y, Sezenöz B, Özkan S, Sivri S, Alsancak AD, et al. Relationship between monocyte/high-density lipoprotein cholesterol ratio and angiographic severity and extent of coronary artery disease. Koşuyolu Heart Journal. 2017;20(1):30-5.
- 21.Sahpolat M, Ayar D, Ari M, Karaman MA. Elevated Monocyte to High-density Lipoprotein Ratios as an Inflammation Markers for Schizophrenia Patients. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. 2021;19(1):112-6.
- 22.Association AP. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR): American Psychiatric Association; 2000.
- 23.Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530(7589):177-83.
- 24.Mazza MG, Capellazzi M, Lucchi S, Tagliabue I, Rossetti A, Clerici M. Monocyte count in schizophrenia and related disorders: a systematic review and meta-analysis. Acta neuropsychiatrica. 2020;32(5):229-36.
- 25.Weber NS, Gressitt KL, Cowan DN, Niebuhr DW, Yolken RH, Severance EG. Monocyte activation detected prior to a diagnosis of schizophrenia in the US Military New Onset Psychosis Project (MNOPP). Schizophrenia research. 2018;197:465-9.
- 26.Misiak B, Stańczykiewicz B, Łaczmański Ł, Frydecka D. Lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis: A systematic review and meta-analysis. Schizophrenia research. 2017;190:18-27.
- 27.Douglas J, Nasrallah HA. Low high-density lipoprotein and psychopathology: A review. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. 2019;31(3):209-13.
- 28.Johnsen SH, Fosse E, Joakimsen O, Mathiesen EB, Stensland-Bugge E, Njølstad I, et al. Monocyte count is a predictor of novel plaque formation: a 7-year follow-up study of 2610 persons without carotid plaque at baseline the Tromsø Study. Stroke. 2005;36(4):715-9.
- 29.Bath PM, Gladwin AM, Martin JF. Human monocyte characteristics are altered in hypercholesterolaemia. Atherosclerosis. 1991;90(2- 3):175-81.
- 30.Murphy AJ, Chin-Dusting JP, Sviridov D, Woollard KJ. The anti inflammatory effects of high density lipoproteins. Current medicinal chemistry. 2009;16(6):667-75.
- 31.Murphy AJ, Woollard KJ. High-density lipoprotein: a potent inhibitor of inflammation. Clinical and experimental pharmacology & physiology. 2010;37(7):710-8.
- 32.Açıkgöz SK, Açıkgöz E, Şensoy B, Topal S, Aydoğdu S. Monocyte to high-density lipoprotein cholesterol ratio is predictive of in-hospital and five-year mortality in ST-segment elevation myocardial infarction. Cardiology journal. 2016;23(5):505-12.
- 33.Yvan-Charvet L, Pagler T, Gautier EL, Avagyan S, Siry RL, Han S, et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science (New York, NY). 2010;328(5986):1689- 93.
- 34.Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. Highdensity lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arteriosclerosis, thrombosis, and vascular biology. 1995;15(11):1987-94.
- 35.Barter P. The role of HDL-cholesterol in preventing atherosclerotic disease. European Heart Journal Supplements. 2005;7(suppl_F):F4-F8.
- 36.Roberts CK, Ng C, Hama S, Eliseo AJ, Barnard RJ. Effect of a shortterm diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. Journal of applied physiology (Bethesda, Md : 1985). 2006;101(6):1727-32.
- 37.Ringen PA, Engh JA, Birkenaes AB, Dieset I, Andreassen OA. Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions. Frontiers in psychiatry. 2014;5:137.
- 38.von Hausswolff-Juhlin Y, Bjartveit M, Lindström E, Jones P. Schizophrenia and physical health problems. Acta psychiatrica Scandinavica Supplementum. 2009(438):15-21.
- 39.Onen S, Taymur I. Evidence for the atherogenic index of plasma as a potential biomarker for cardiovascular disease in schizophrenia. Journal of psychopharmacology (Oxford, England). 2021;35(9):1120-6.
| APA | Candemir M, CANSIZ A (2022). Predictive Value of Monocyte to High-Density Lipoprotein Cholesterol Ratio (MHR) in Schizophrenia Patients with Stable Coronary Artery Disease. , 77 - 83. 10.54005/geneltip.1032165 |
| Chicago | Candemir Mustafa,CANSIZ Alparslan Predictive Value of Monocyte to High-Density Lipoprotein Cholesterol Ratio (MHR) in Schizophrenia Patients with Stable Coronary Artery Disease. (2022): 77 - 83. 10.54005/geneltip.1032165 |
| MLA | Candemir Mustafa,CANSIZ Alparslan Predictive Value of Monocyte to High-Density Lipoprotein Cholesterol Ratio (MHR) in Schizophrenia Patients with Stable Coronary Artery Disease. , 2022, ss.77 - 83. 10.54005/geneltip.1032165 |
| AMA | Candemir M,CANSIZ A Predictive Value of Monocyte to High-Density Lipoprotein Cholesterol Ratio (MHR) in Schizophrenia Patients with Stable Coronary Artery Disease. . 2022; 77 - 83. 10.54005/geneltip.1032165 |
| Vancouver | Candemir M,CANSIZ A Predictive Value of Monocyte to High-Density Lipoprotein Cholesterol Ratio (MHR) in Schizophrenia Patients with Stable Coronary Artery Disease. . 2022; 77 - 83. 10.54005/geneltip.1032165 |
| IEEE | Candemir M,CANSIZ A "Predictive Value of Monocyte to High-Density Lipoprotein Cholesterol Ratio (MHR) in Schizophrenia Patients with Stable Coronary Artery Disease." , ss.77 - 83, 2022. 10.54005/geneltip.1032165 |
| ISNAD | Candemir, Mustafa - CANSIZ, Alparslan. "Predictive Value of Monocyte to High-Density Lipoprotein Cholesterol Ratio (MHR) in Schizophrenia Patients with Stable Coronary Artery Disease". (2022), 77-83. https://doi.org/10.54005/geneltip.1032165 |
| APA | Candemir M, CANSIZ A (2022). Predictive Value of Monocyte to High-Density Lipoprotein Cholesterol Ratio (MHR) in Schizophrenia Patients with Stable Coronary Artery Disease. Genel Tıp Dergisi, 32(1), 77 - 83. 10.54005/geneltip.1032165 |
| Chicago | Candemir Mustafa,CANSIZ Alparslan Predictive Value of Monocyte to High-Density Lipoprotein Cholesterol Ratio (MHR) in Schizophrenia Patients with Stable Coronary Artery Disease. Genel Tıp Dergisi 32, no.1 (2022): 77 - 83. 10.54005/geneltip.1032165 |
| MLA | Candemir Mustafa,CANSIZ Alparslan Predictive Value of Monocyte to High-Density Lipoprotein Cholesterol Ratio (MHR) in Schizophrenia Patients with Stable Coronary Artery Disease. Genel Tıp Dergisi, vol.32, no.1, 2022, ss.77 - 83. 10.54005/geneltip.1032165 |
| AMA | Candemir M,CANSIZ A Predictive Value of Monocyte to High-Density Lipoprotein Cholesterol Ratio (MHR) in Schizophrenia Patients with Stable Coronary Artery Disease. Genel Tıp Dergisi. 2022; 32(1): 77 - 83. 10.54005/geneltip.1032165 |
| Vancouver | Candemir M,CANSIZ A Predictive Value of Monocyte to High-Density Lipoprotein Cholesterol Ratio (MHR) in Schizophrenia Patients with Stable Coronary Artery Disease. Genel Tıp Dergisi. 2022; 32(1): 77 - 83. 10.54005/geneltip.1032165 |
| IEEE | Candemir M,CANSIZ A "Predictive Value of Monocyte to High-Density Lipoprotein Cholesterol Ratio (MHR) in Schizophrenia Patients with Stable Coronary Artery Disease." Genel Tıp Dergisi, 32, ss.77 - 83, 2022. 10.54005/geneltip.1032165 |
| ISNAD | Candemir, Mustafa - CANSIZ, Alparslan. "Predictive Value of Monocyte to High-Density Lipoprotein Cholesterol Ratio (MHR) in Schizophrenia Patients with Stable Coronary Artery Disease". Genel Tıp Dergisi 32/1 (2022), 77-83. https://doi.org/10.54005/geneltip.1032165 |
